pt
updat sales/ep estim cc cc
sell day sd adj report exhibit
estim compar consensu
 guidanc cc
model gross margin/oper margin/
tax rate prior pt
base weight suggest rel valuat
framework weight dcf maintain buy
suppli issu improv fda worri abat new product
improv outlook believ made good progress
suppli recoveri front reduc backlog order increas safeti
inventori level longer consid issu obstacl
accomplish turnaround timelin avail product critic
step enabl salesforc rebuild custom confid increas servic
level improv suppli chain effici compani continu
ramp product launch throughout qualiti remedi front
expect readi fda re-inspect end share
manag view flagship knee franchis draw much
investor attent rebound full launch persona revis
cement-less partial offer well introduct rosa robot
solut point friday link rosa pre-plan
intra-op simul allow person afford persona
system shine forth much less painless way share view zbh
manag robot import sourc mix upsid market
share sticki link rosa spine robot releas
also help drive share asp stabil spinal implant
also look forward improv perform set emea continu
solid perform asiapac margin front still hinder
averag product cost associ over-reli manual
production/control process well invest support new product
introduct margin expans well expans evid
overal last year turn-around
progress evid cours year continu pay-down debt
estim debt adjust ebitda ratio declin
across period set compani acquisit
activ order improv market weight growth rate
continu pg
tr target
valuat thesi risk price target base weight dcf valu
assum top-lin acceler ultim improv
pre-tax margin employ discount rate termin
growth rate weight rel valuat framework valu rel
valuat framework regress year top-lin expect rel forward multipl larger
cap med tech compani period incorpor compound-annual-growth-rate estim
suggest rel forward multipl multipli month averag
market multipl yield target forward multipl multipli
estim ep month henc arriv rel valuat valu view
suit longer term holder patienc stabil core busi
diversif effort move compani higher market wagr dcf captur
potenti zbh intrins valu presum good execut success diversif wherea
rel valuat captur current realiti remain buy rate valuat remain
unchalleng manag seem make right move improv perform
part due key new product rosa robot seem creat favor risk reward
oper perform improv diversif becom tangibl credit may
ascrib intrins valu risk includ execut misstep inclus failur remedi
product suppli shortfal lead continu under-perform vs end market sluggish
anticip major joint market issuanc fda warn letter could interfer
suppli and/or new product introduct and/or new product introduct misstep inclus
page
page
page
million except per share interest expens inc analysisgross cmf sale sale cc/sd/divest sale inc inc
zimmer lead player musculoskelet devic segment player hip
ww share knee meaning presenc musculoskelet categori dental
cmf/thorac surgic sport medicin extrem trauma
spine ex-ldrh spun parent august headquart
believ suit longer term holder patienc stabil
core busi diversif effort move compani higher market wagr
dcf captur potenti zbh intrins valu presum good execut success
diversif wherea rel valuat captur current realiti remain buy rate
think valuat remain unchalleng manag seem make right
move improv perform expect part due key new product
rosa robot seem creat favor risk/reward oper perform improv
diversif becom tangibl expect credit may ascrib intrins valu
valuat risk
price target base weight dcf valu assum top-lin
acceler ultim improv pre-tax margin
employ discount rate termin growth rate weight
rel valuat framework valu rel valuat framework regress year
top-lin expect rel forward multipl larger cap med tech compani
period incorpor compound-annual-growth-rate estim suggest rel forward
multipl multipli month averag market multipl yield
target forward multipl multipli estim ep month
henc arriv rel valuat valu risk includ execut misstep
inclus failur remedi product suppli shortfal lead continu under-perform vs
end market sluggish anticip major joint market issuanc fda warn letter
could interfer suppli and/or new product introduct and/or new product introduct
misstep inclus rosa tka robot
compani mention note
bruce nudel herebi certifi view express research report accur reflect
person view subject compani secur also certifi
receiv direct indirect compens exchang express specif
recommend report
